Research

Keeping Our Eyes to the Future

According to the National Eye Institute, more than 3.5 million Americans are blind or suffer from some type of visual impairment. Sadly, that number is expected to nearly double by the year 2030 if more isn’t done to detect and treat eye disease earlier. At Illinois Retina Associates, we’re committed to preserving the gift of sight.

Through research, clinical studies, teaching, and the development of new instruments and techniques, our doctors are leading the way in advancing the field of retina medicine and surgery. But that kind of commitment requires significant funding. That’s why Illinois Retina Associates has created the Eyes to the Future Foundation. Eyes to the Future helps fund clinical research studies and educate future retinal specialists – with the singular goal of preserving the gift of sight.

Clinical Research

The future of retina care lies in the unending pursuit of new knowledge and technology. At Illinois Retina Associates, we participate in numerous research studies conducted by the National Institutes of Health (NIH), the National Eye Institute (NEI), and the Food and Drug Administration (FDA). Our physicians serve as principal investigator or co-investigator in dozens of clinical trials that cover every aspect of vitreoretinal disease and treatment, including:

  • Age-Related Macular Degeneration
  • Diabetic Retinopathy
  • Retinal Detachment
  • Central Vein Occlusion
  • Branch Vein Occlusion
  • Vitreoretinopathy
  • Macular Hole
  • CMV Retinitis
  • Retinopathy of Prematurity
  • Endophthalmitis Vitrectomy
  • Scleral Buckle
  • And many more.

Open clinical trials

The future of retina care lies in the vigorous pursuit of new knowledge and improved technology. From the very beginning, Illinois Retina Associates has been committed to advancing the field of retina care through clinical research. We have participated in numerous research studies conducted by the National Institutes of Health (NIH), the National Eye Institute (NEI) and the Food and Drug Administration (FDA).

Our physicians have served as principal investigator or co-investigator in dozens of clinical trials that cover every aspect of vitreoretinal disease and treatment, including:

  • Age-related Macular Degeneration
  • Diabetic Retinopathy
  • Retinal Detachment
  • Central Vein Occlusion
  • Branch Vein Occlusion
  • Vitreoretinopathy
  • Macular Hole
  • CMV Retinitis
  • Retinopathy of Prematurity
  • Endophthalmitis Vitrectomy
  • Scleral Buckle
  • And many more.

Active Enrolling Trials

Retinal Vein Occlusion

Criteria: Comparison of Avastin vs. Lucentis in the treatment of macular edema following retinal vein occlusion.
Primary Investigators: John S. Pollack, MD; Joseph M. Civantos, MD
Primary Contact: Barb Ciscato
Location: Joliet
Billing information: All study visits, testing, procedures and drug will be billed to patient’s insurance.

Non-Central Involved DME

Clinical Criteria: To assess the effects of NSAIDs on macular retinal volume compared with placebo in eyes with non-central DME.
Primary Investigators: John S. Pollack, MD
Primary Contact: Barb Ciscato
Location: Joliet
Billing information: OCTs and Fas required at study visits are to be billed as NC to the patients. The following visits/procedures are considered part of standard care and should be billed to the patient’s insurance: eye exam, OCT at non-protocol DME treatment visits, non-protocol treatment for DME or diabetic retinopathy, any additional visits not specified per protocol.

Uveitis

Clinical Criteria: Double masked study assessing the safety and efficacy of intravitreal injection of DE-109 (sirolimus) 3 doses for the treatment of active non-infectious uveitis of the posterior segment.
Primary Investigators: Pauline T. Merrill, MD
Primary Contact: Michelle Woo
Location: Oak Park
Billing information: Nothing is charged to patient at all. Study pays for everything.


Previous Trial Experience

Age-Related Macular Degeneration

  • VFQ-25 – Visual Function Questionnaire
  • AREDS2 – Age-Related Eye Disease Study 2/li>
  • CLOVER – Combination Lucentis & OPT with Visudyne with Evaluation-based Treatments
  • Alcon AART – Alcon Anecortave Risk Reduction
  • AMD – Age-Related Macular Degeneration Chart Review Study
  • Alcon Anecortave Acetate
  • AREDS – Age-Related Eye Disease Study
  • Macugen Injections/de novo lesions – Chart Review Study
  • Macugen Injections – Chart Review Study
  • Eye Tech Study
  • PreView PHP – Preferential Hyperactivity Perimeter
  • SST – Submacular Surgery Trials
  • VER – Visudyne in Early Retreatment of Exudative ARMD with CNV
  • VIM – Visudyne in Minimally Classic CNV from ARMD
  • Cabernet Trial – CNV following AMD Treated with Beta Radiation Epiretinal Therapy
  • Sailor Study
  • CAPT Study- Complications in Age-Related Macular Degeneration Prevention Trial
  • CATT – Comparison of Age-Related Macular Degneration Treatment Trials

Diabetic Eye Disease

  • DRCR Protocol I
  • DRCR Protocol J
  • READ-2 Study – Ranibizumab (Lucentis) alone vs. Combination with Laser for Diabetic Macular Edema
  • CDS – Controlled Delivery Study
  • DRCR ISI vs. Laser for Diabetic Macular Edema
  • DRCR Protocol H – Bevacizumab (Avastin) vs. Laser for DME
  • DRCR Protocol H Laser for DME
  • DMEVS – Diabetic Macular Edema Vitrectomy Study
  • Ranibizumab (Lucentis) for Diabetic Macular Edema
  • Allergan DEX PS DDS – DME with Laser vs. Laser alone
  • SurModics, Phase II
  • FAME Study

Vascular Occlusive Disease

  • SCORE – Standard Care vs. Corticosteroid for CRVO and BRVO

These are active or past studies which our doctors have served as principal investigators or co-investigators.